Physician

James Frederic Beekman, MD

According to 2025 Medicare claims, James Beekman, MD (NPI: 1043221013) practices rheumatology in the Greensboro-High Point, NC market, with the plurality of this provider's patient population coming from Guilford, NC. This provider's primary affiliated billing organization is GREENSBORO RHEUMATOLOGY, P.A. (NPI: 1497100721; TIN: 811945325) and primary practice location at 27410-9700. Beekman is affiliated with the Triad HealthCare Network, LLC. (ACO ID: D0209), participating under the REACH model.

Beekman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 393 traditional Medicare patients, billed 212,109 HCPCS/CPT codes, and received $2,326,019 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 3,792 prescription claims across 612 beneficiaries totaling $3,620,874 in drug costs, led by Enbrel Sureclick (Etanercept). Open Payments data shows 209 records totaling $24,821. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,438,260 to $3,620,874. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	575	62,161	$1,842,338
2016	647	95,438	$2,339,851
2017	459	125,577	$2,761,971
2018	515	142,316	$3,366,507
2019	505	152,095	$3,457,464
2020	474	163,070	$3,210,521
2021	501	172,479	$2,748,059
2022	473	189,999	$2,351,725
2023	429	191,279	$2,242,751
2024	393	212,109	$2,326,019

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	671	6,039	$1,438,260
2016	720	5,438	$1,528,642
2017	551	4,095	$1,368,888
2018	596	4,401	$1,587,284
2019	598	4,439	$1,933,066
2020	595	4,287	$2,135,850
2021	593	4,231	$2,223,292
2022	635	4,167	$2,709,071
2023	635	4,203	$3,505,996
2024	612	3,792	$3,620,874

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	65	257	$92
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	264	508	$87
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	122	620	$45
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	260	490	$12
J1602	Injection, golimumab, 1 mg, for intravenous use	80	56,650	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enbrel Sureclick	Etanercept	152	4,480	$1,181,240
Humira(Cf) Pen	Adalimumab	110	3,086	$886,616
Orencia Clickject	Abatacept	57	1,596	$320,293
Taltz Autoinjector	Ixekizumab	26	728	$181,903
Rinvoq	Upadacitinib	23	750	$154,949

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	209	$24,821	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for James Frederic Beekman, MD?

Tedicare shows public-source Medicare data for James Frederic Beekman, MD (NPI 1043221013), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does James Frederic Beekman, MD have ACO affiliation data?

James Frederic Beekman, MD is shown with ACO affiliation data for Triad HealthCare Network, LLC. (REACH, ACO ID D0209).

What billing organization is linked to James Frederic Beekman, MD?

James Frederic Beekman, MD is linked to GREENSBORO RHEUMATOLOGY, P.A. (billing NPI 1497100721) in the available physician profile data.

Does James Frederic Beekman, MD have Open Payments data?

James Frederic Beekman, MD has 209 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.